Suzanne Ranger

Amplification of flecainide-induced ventricular conduction slowing by exercise. A potentially significant clinical consequence of use-dependent sodium channel blockade.

Suzanne Ranger, Mario Talajic, Robert Lemery et al. · Circulation · 1989 · 116 citations · Full text

Significant Clinical Consequence, Sinus Tachycardia, Cardiac Muscle +19

Erythromycin-induced long QT syndrome: Concordance with quinidine and underlying cellular electrophysiologic mechanism

Stanley Nattel, Suzanne Ranger, Mario Talajic et al. · The American Journal of Medicine · 1990 · 106 citations

Pharmacology, Pathology, Cellular Electrophysiologic Mechanism +2

Determinants and Mechanisms of Flecainide-Induced Promotion of Ventricular Tachycardia in Anesthetized Dogs

Suzanne Ranger, Stanley Nattel · Circulation · 1995 · 45 citations

Kinetics of use-dependent ventricular conduction slowing by antiarrhythmic drugs in humans.

Suzanne Ranger, Mario Talajic, Robert Lemery et al. · Circulation · 1991 · 43 citations · Full text

Modulation of flecainide's cardiac sodium channel blocking actions by extracellular sodium: a possible cellular mechanism for the action of sodium salts in flecainide cardiotoxicity.

Suzanne Ranger, Robert S. Sheldon, Bernard Fermini et al. · Journal of Pharmacology and Experimental Therapeutics · 1993 · 40 citations